418PDNCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. (23rd October 2018) - Janku, F; Jegede, O; Puhalla, S L; Konstantinopoulos, P; Meric-Bernstam, F; Mitchell, E P; Zwiebel, J A; McShane, L M; Li, S; Rubinstein, L V; Doyle, L A; Patton, D; et al.